VPGMarketResearch.com's new report is a strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years. The report examines key German market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology testing market, in evaluating emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Opportunities and Strategic Recommendations
- Emerging opportunities for new instrumentation,
reagents kits, IT and other products with significant market
appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter,
Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium,
Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea,
Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme disease,
Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps,
Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Market Segmentation Analysis
- Sales and market shares of major suppliers
by individual test.
- Volume and sales forecasts for over 100 infectious disease
assays by individual test and market segment:
° Blood Banks
° Commercial/Private Laboratories
- Test volume estimates by method (molecular, serology/immunodiagnostics,
- Review of the market dynamics, trends,
structure, size, growth and major suppliers.
Current and Emerging Products
- In-depth examination of over 100 major diseases,
including their etiology, current diagnostic tests,
vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease
testing, including their operating
characteristics, features and selling prices.
- Assessment of molecular diagnostic, monoclonal antibody,
immunoassay, and other technologies and their potential
applications for infectious disease testing.
- Global listings of companies developing or
marketing infectious disease diagnostic products
by individual test.
- Strategic assessments of major suppliers and
emerging market entrants, including their sales, product
portfolios, marketing tactics, collaborative
arrangements and new products in R&D.
Contains 983 pages and 160 tables